trial// Lancet. – 1983. – V. 2. – Р. 986–989.
3] Pescovitz M.D., Barone G., Choc M.G. Jr et al. Safety and tolerability of cyclosporine micro-emulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group// Transplantation. – 1997. – V. 63. – Р. 778–780.
[4] Pollard S.G., Lear P.A., Ready A.R. et al. Comparison of micro-emulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The UK Neoral Renal Study Group// Transplantation. – 1999. – V. 68. – Р. 1325–1331.
[5] Pirsch J.D., Miller J., Deierhoi M.H. et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group// Transplantation. – 1997. – V. 63. – Р. 977–983.
[6] Mayer A.D., Dmitrewski J., Squifflet J.P. et al. Multicenter randomised trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicentre Renal Study Group// Transplantation. – 1997. – V. 64. – Р. 436–443.
